Slide 1: SYNBV and AdAlta: Delivering next generation cellular immunotherapies
SYNBV and AdAlta: Delivering next generation cellular immunotherapies AdAlta Limited (ASX:1AD) A modern targeting system for next generation drugs Investor Webinar 10 April 2024
Slide 2: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 3: SYNthesis BioVentures is partnering with AdAlta
SYNthesis BioVentures (SYNBV) is partnering with AdAlta to develop next generation cellular immunotherapies for solid cancers Memorandum of Understanding 6-12 months initial collaboration • i-body platform: building blocks for • Deep China experience next generation cell therapies • Cross border tra
Slide 4: Memorandum of Understanding advances a key AdAlta growth strategy
Memorandum of Understanding advances a key AdAlta growth strategy AdAlta’s three core strategies Current status Partnering discussions advancing well for: 1. Realise the value of lead asset AD-214 Out-licensing; or Co-development/asset financing Advanced therapies partnering opportunities 3 ac
Slide 5: The cellular immunotherapy opportunity
The cellular immunotherapy opportunity
Slide 6: Cellular immunotherapies are transforming cancer outcomes
Cellular immunotherapies are transforming cancer outcomes New, multifunctional therapies are needed to address solid cancers Therapy involves re-engineering patient’s own immune cells to “see” cancer – living drug, single dose, potentially curative 6 FDA-approved CAR-T therapies since 2017 transform
Slide 7: Cell and gene therapy up front deal values
Cell and gene therapy up front deal values 3.5x higher than other biologic drugs with early partnering potential Asset in-licensing terms Pre-clinical proof of concept cell therapy transactions Cell & gene therapy Biologics Upfront/ Deal value/ No. of 120 Date Licensee Licensor target target assets
Slide 8: AdAlta's "east to west" cellular immunotherapy strategy
AdAlta’s “east to west” cellular immunotherapy strategy
Slide 9: Three insights support AdAlta and AdCella's vision and opportunity
Three insights support AdAlta and AdCella’s vision and opportunity in cellular immunotherapy Asia is global epicentre of innovation in cellular immunotherapy; supportive regulatory system enables early clinical data to derisk assets AdAlta’s i-body® technology is ideally suited to multifunctional pr
Slide 10: Eastern hemisphere has the richest cellular immunotherapy development pipeline
Eastern hemisphere has the richest cellular immunotherapy development pipeline in the world Cellular immunotherapy developers 20231 Cellular immunotherapy clinical trials 20242 n = 1,104 n = 1804 1108 Other South Korea 11 28 47 Japan 50 Australia 449 439 583 185 49 Canada China 972 31 Asia Pacific N
Slide 11: Australia has a well-developed cell therapy delivery ecosystem
Australia has a well-developed cell therapy delivery ecosystem1 Clinical delivery capability • 138 cell and gene therapy trials to date • 55 institutions treating patients with cell and gene therapies • 25 sites approved for commercial CAR-T delivery • 3 commercial approvals for CAR-T products • Cli
Slide 12: AdAlta's i-bodies enable superior CAR constructs
AdAlta’s i-bodies enable superior CAR constructs (i-CARs) and other advanced therapies when combined with partner platforms TINY i-body® needs LESS room in inserted gene, i-CAR-T example i-body enabling MORE engineered function Targeting domain Produces superior, multifunctional advanced therapy Tum
Slide 13: A unique combination of local and regional capabilities secures AdCella's advantage
A unique combination of local and regional capabilities secures AdCella’s advantage – strengthened by SYNBV collaboration World class advanced therapies clinical trial and translational research Experienced GMP manufacturing Geographic, time zone and and supply chain economic connectivity with produ
Slide 14: Key terms of AdAlta-SYNBV collaboration
Key terms of AdAlta-SYNBV collaboration Success = AdCella Ownership: 75% AdAlta 25% SYNBV AdCella before financing of initial assets (so may change over time) License: to ex-Asia rights for near to clinic novel cellular immunotherapies for solid Raise capital for cancers first western Secure licensi
Slide 15: AdAlta is evaluating a pipeline of substantially de-risked assets
AdAlta is evaluating a pipeline of substantially de-risked assets: examples Project: Tamworth Project: Jiansgu Project: Seoul Origin: China Origin: China Origin: South Korea Target: Known class, unusual peptide Target: Known, superior specificity Target: Novel Format: TCR-T cell Format: CAR-T Format
Slide 16: Why AdAlta should develop a cell therapy company?
Why AdAlta should develop a cell therapy company? Cellular immuno- Highly differentiated Rich pipeline of Scalable business Strong team and therapy for solid competitive position: differentiated model allowing for partnership with tumours is a large, • Eastern product candidates, multiple programs S
Slide 17: Cellular immunotherapy is just one part of AdAlta's partnering strategy
Cellular immunotherapy is just one part of AdAlta’s partnering strategy Near term partnering opportunities Progressing satisfactorily 1. Realise the value of lead asset AD-214 Out-licensing; or Co-development/asset financing Co-development collaborations in 2. Progress i-CAR and i-PET programs
Slide 18: A modern targeting system for next generation drugs
A modern targeting system for next generation drugs AdAlta Ltd (ASX:1AD) For more information please contact: Tim Oldham CEO & Managing Director +61 403 446 665 t.oldham@adalta.com.au Investor Relations The Capital Network Russell Katz +61 2 8999 3699 russell@thecapitalnetwork.com.au www.adalta.com.